Notably, mutation of a subdomain in the N-terminus of CDX2 has been reported to abrogate the anti-proliferative effects of CDX2, which may be via inhibition of β-catenin/T-cell factor (TCF) transcriptional activity by disrupting the β-catenin-TCF protein complex in colon cancer cells (37). The gene discussed is CDX2; the disease is colonic neoplasm.